Genetic mechanisms of critical illness in Covid-19

Erola Pairo-Castineira,Sara Clohisey,Lucija Klaric,Andrew Bretherick,Konrad Rawlik,Nick Parkinson,Dorota Pasko,Susan Walker,Anne Richmond,Max Head Fourman,Clark D Russell,Andrew Law,James Furniss,Elvina Gountouna,Nicola Wrobel,Loukas Moutsianas,Bo Wang,Alison Meynert,Zhijian Yang,Ranran Zhai,Chenqing Zheng,Fiona Griffiths,Wilna Oosthuyzen,Graeme Grimes,Barbara Shih,Sean Keating,Marie Zechner,Chris Haley,David J. Porteous,Caroline Hayward,Julian Knight,Charlotte Summers,Manu Shankar-Hari,Paul Klenerman,Lance Turtle,Antonia Ho,Charles Hinds,Peter Horby,Alistair Nichol,David Maslove,Lowell Ling,Danny McAuley,Hugh Montgomery,Timothy Walsh,The GenOMICC Investigators,The ISARIC-4C Investigators,The Covid-19 Human Genetics Initiative,Xia Shen,Kathy Rowan,Angie Fawkes,Lee Murphy,Chris P. Ponting,Albert Tenesa,Mark Caulfield,Richard Scott,Peter J.M. Openshaw,Malcolm G. Semple,Veronique Vitart,James F. Wilson,J. Kenneth Baillie,,,

DOI: https://doi.org/10.1101/2020.09.24.20200048

2020-09-25

Abstract:Abstract The subset of patients who develop critical illness in Covid-19 have extensive inflammation affecting the lungs 1 and are strikingly different from other patients: immunosuppressive therapy benefits critically-ill patients, but may harm some non-critical cases. 2 Since susceptibility to life-threatening infections and immune-mediated diseases are both strongly heritable traits, we reasoned that host genetic variation may identify mechanistic targets for therapeutic development in Covid-19. 3 GenOMICC (Genetics Of Mortality In Critical Care, genomicc.org ) is a global collaborative study to understand the genetic basis of critical illness. Here we report the results of a genome-wide association study (GWAS) in 2244 critically-ill Covid-19 patients from 208 UK intensive care units (ICUs), representing >95% of all ICU beds. Ancestry-matched controls were drawn from the UK Biobank population study and results were confirmed in GWAS comparisons with two other population control groups: the 100,000 genomes project and Generation Scotland. We identify and replicate three novel genome-wide significant associations, at chr19p13.3 (rs2109069, p = 3.98 × 10 −12 ), within the gene encoding dipeptidyl peptidase 9 ( DPP9 ), at chr12q24.13 (rs10735079, p =1.65 × 10 −8 ) in a gene cluster encoding antiviral restriction enzyme activators ( OAS1, OAS2, OAS3 ), and at chr21q22.1 (rs2236757, p = 4.99 × 10 −8 ) in the interferon receptor gene IFNAR2 . Consistent with our focus on extreme disease in younger patients with less comorbidity, we detect a stronger signal at the known 3p21.31 locus than previous studies (rs73064425, p = 4.77 × 10 −30 ). We identify potential targets for repurposing of licensed medications. Using Mendelian randomisation we found evidence in support of a causal link from low expression of IFNAR2 , and high expression of TYK2 , to life-threatening disease. Transcriptome-wide association in lung tissue revealed that high expression of the monocyte/macrophage chemotactic receptor CCR2 is associated with severe Covid-19. Our results identify robust genetic signals relating to key host antiviral defence mechanisms, and mediators of inflammatory organ damage in Covid-19. Both mechanisms may be amenable to targeted treatment with existing drugs. Large-scale randomised clinical trials will be essential before any change to clinical practice.